Telormedix has successfully completed the safety portion of a Phase 1/2 trial for TMX-101. This three-part trial is an open-label, multicenter, dose escalation study.
A Citi Investment Research analyst has begun covering drugmaker ChemoCentryx with a "Buy" rating. ChemoCentryx's partner, GlaxoSmithKline plc, is conducting late-stage clinical trials of Traficet for Crohn's disease.
Researchers analyzed data from the JUPITER trial, a randomized, double-blind trial with placebo control groups conducted at 1,315 sites in 26 countries to look at the use of the statin rosuvastatin in disease prevention.
Drug makers AstraZeneca and Targacept say they have abandoned plans to seek regulatory approval for a drug intended to treat major depressive disorder.
PaxVax Corporation announced that the U.S. Food and Drug Administration has accepted its investigational new drug application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials.
Traceability describes the ability to verify the origin, location, or application of an item by means of documented recorded identification.
In molecular medicine, nucleic acids are being extensively investigated for use in gene therapy and in genetic vaccinations in which foreign nucleic acid is translated into proteins by the host cells.
Days after its most advanced drug candidate failed in a late-stage trial, Anthera Pharmaceuticals Inc. said it will eliminate about half its staff positions.
Abbott has initiated two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of Humira (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa.
Endocyte Inc. said it is close to restarting a clinical trial of its experimental cancer drug, EC145, as well as filing for conditional marketing approval in Europe.
Drug developer Tranzyme Inc. said its most advanced drug candidate failed in a clinical trial. Tranzyme was testing ulimorelin to see if the drug helped patients recover their gastrointestinal function after surgery.
Medivir AB has announced that its oral, once daily investigational protease inhibitor TMC435—developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus—has commenced two Phase 3 clinical trials.
Anthera Pharmaceuticals Inc. said it stopped a late-stage clinical trial of its cardiovascular disease drug varespladib because the drug was not working.
Pfizer Inc. said it is ending a safety study of its pain drug Celebrex because of difficulty finding patients. The trial was designed to measure the effects of Celebrex on patients who were taking the drug to treat juvenile idiopathic arthritis.
Cleveland BioLabs, Inc. announced that the first patient completed an initial series of five doses in a Phase 1 trial evaluating CBLB502 in advanced cancer patients.
Cytheris SA announces results from a Phase 2 study designed to investigate the potential of CYT107 therapy to reconstitute CD4 T-cells in chronically HIV-1 infected patients whose T-cell counts remained low despite treatment with antiretroviral therapies.
Johnson & Johnson said that its prostate cancer pill Zytiga improved survival and delayed the progression of cancer in patients who had not been treated with chemotherapy.
Astex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has issued a Complete Response Letter to partner Eisai for their supplemental New Drug Application for Dacogen for Injection for patients with acute myeloid leukemia.
Circassia has successfully completed a large-scale Phase 2 clinical study of its ToleroMune ragweed allergy treatment. Ragweed pollen is one of the main allergens responsible for hayfever in the Unite States and its prevalence is increasing across Europe.
Glaucoma is not just one, but a group of diseases that lead to irreversible damage to the optic nerve resulting in permanent loss of vision. Although there is currently no cure, significant advances are being made by researchers and companies for the successful management of glaucoma.
Teva Pharmaceutical Industries Ltd. announced positive findings from four Phase 3 clinical studies that examined the efficacy and safety of QNASL in treating allergic rhinitis.
ICON plc announced that it has been selected by Roche as its technology partner for storing and managing medical images collected during the company’s clinical research programs.
Drugmaker SciClone Pharmaceuticals Inc. will end its development of SCV-07, a treatment for oral mucositis, an inflammatory side effect of chemotherapy for head and neck cancer.
BioInvent International AB and its collaborator Genentech announced that all patients have completed enrollment in the GLACIER study, a Phase 2a study with BI-204 in patients with stable atherosclerotic vascular disease.
Tranzyme Pharma and Norgine B.V. have completed patient enrollment in ULISES 008, the second of two Phase 3 trials of ulimorelin for the acceleration of gastrointestinal recovery in patients undergoing abdominal surgery.